[go: up one dir, main page]

PL3600309T3 - Skojarzenia terapeutyczne do leczenia chorób wątroby - Google Patents

Skojarzenia terapeutyczne do leczenia chorób wątroby

Info

Publication number
PL3600309T3
PL3600309T3 PL18717800.9T PL18717800T PL3600309T3 PL 3600309 T3 PL3600309 T3 PL 3600309T3 PL 18717800 T PL18717800 T PL 18717800T PL 3600309 T3 PL3600309 T3 PL 3600309T3
Authority
PL
Poland
Prior art keywords
liver diseases
treating liver
therapeutic combinations
therapeutic
combinations
Prior art date
Application number
PL18717800.9T
Other languages
English (en)
Inventor
Jamie Geier BATES
David Gordon Clarkson Breckenridge
John T. Liles
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of PL3600309T3 publication Critical patent/PL3600309T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL18717800.9T 2017-03-28 2018-03-26 Skojarzenia terapeutyczne do leczenia chorób wątroby PL3600309T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762477697P 2017-03-28 2017-03-28
US201762482105P 2017-04-05 2017-04-05
US201762586354P 2017-11-15 2017-11-15
PCT/US2018/024345 WO2018183193A1 (en) 2017-03-28 2018-03-26 Therapeutic combinations for treating liver diseases

Publications (1)

Publication Number Publication Date
PL3600309T3 true PL3600309T3 (pl) 2022-11-07

Family

ID=61972244

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18717800.9T PL3600309T3 (pl) 2017-03-28 2018-03-26 Skojarzenia terapeutyczne do leczenia chorób wątroby
PL22180249.9T PL4122464T3 (pl) 2017-03-28 2018-03-26 Kombinacje terapeutyczne do leczenia chorób wątroby

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL22180249.9T PL4122464T3 (pl) 2017-03-28 2018-03-26 Kombinacje terapeutyczne do leczenia chorób wątroby

Country Status (13)

Country Link
US (3) US20180280394A1 (pl)
EP (3) EP4122464B1 (pl)
JP (2) JP6906626B2 (pl)
KR (3) KR20240091322A (pl)
CN (1) CN110461328A (pl)
AU (2) AU2018243719B2 (pl)
CA (1) CA3055581C (pl)
ES (2) ES2982801T3 (pl)
PL (2) PL3600309T3 (pl)
PT (2) PT3600309T (pl)
SI (2) SI3600309T1 (pl)
TW (1) TWI663975B (pl)
WO (1) WO2018183193A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
ME03425B (me) 2015-07-06 2020-01-20 Gilead Sciences Inc Cot modulatori i postupci za njihovu upotrebu
KR102269305B1 (ko) 2016-06-13 2021-06-25 길리애드 사이언시즈, 인코포레이티드 Fxr (nr1h4) 조정 화합물
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
PL3600309T3 (pl) 2017-03-28 2022-11-07 Gilead Sciences, Inc. Skojarzenia terapeutyczne do leczenia chorób wątroby
AR114930A1 (es) 2017-09-12 2020-11-11 Novartis Ag Composición farmacéutica
KR20220103807A (ko) 2017-10-06 2022-07-22 길리애드 사이언시즈, 인코포레이티드 Acc 억제제를 포함하는 조합 요법
CN117105933A (zh) 2018-10-31 2023-11-24 吉利德科学公司 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
CA3117556A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
CN113302190B (zh) * 2019-01-15 2024-10-18 吉利德科学公司 Fxr(nr1h4)调节化合物
CA3129949C (en) 2019-02-19 2024-04-30 Gilead Sciences, Inc. Solid forms of fxr agonists
US20200315972A1 (en) * 2019-03-11 2020-10-08 Gilead Sciences, Inc. Formulations of a compound and uses thereof
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
TW202235416A (zh) 2019-06-14 2022-09-16 美商基利科學股份有限公司 Cot 調節劑及其使用方法
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
US20220347190A1 (en) * 2019-09-19 2022-11-03 Novartis Ag Treatment comprising fxr agonists
CN114786676A (zh) * 2019-11-26 2022-07-22 田边三菱制药株式会社 人的非酒精性脂肪性肝炎的预防药或治疗药
KR20220161438A (ko) 2020-03-30 2022-12-06 길리애드 사이언시즈, 인코포레이티드 Cot 억제제 화합물, (S)-6-(((1-(바이사이클로[1.1.1]펜탄-1-일)-1H-1,2,3-트라이아졸-4-일)2-메틸-1-옥소-1,2-다이하이드로아이소퀴놀린-5-일)메틸)))아미노8-클로로-(네오펜틸아미노)퀴놀린-3-카르보니트릴의 고체 형태
KR20220160645A (ko) 2020-04-02 2022-12-06 길리애드 사이언시즈, 인코포레이티드 Cot 저해제 화합물의 제조 방법
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
US12091404B2 (en) 2021-03-11 2024-09-17 Gilead Sciences, Inc. GLP-1R modulating compounds
CA3214961A1 (en) 2021-03-29 2022-10-06 Gilead Sciences, Inc. Khk inhibitors
TW202304435A (zh) 2021-06-04 2023-02-01 美商基利科學股份有限公司 治療ｎａｓｈ之方法
TW202311256A (zh) 2021-06-18 2023-03-16 美商基利科學股份有限公司 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑
IL301945A (en) 2023-04-04 2024-11-01 Yeda Res & Dev A method and a system for predicting diseases related to the liver

Family Cites Families (246)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ193011A (en) 1979-03-19 1983-03-15 Ici Australia Ltd Diarylamine derivatives intermediates herbicidal compositions
US4670560A (en) 1986-04-28 1987-06-02 Ortho Pharmaceutical Corporation Thienopyrimidine-2,4-dione derivatives and intermediates thereof
EP0287959B1 (de) 1987-04-21 1993-04-28 BASF Aktiengesellschaft p-Phenoxy-phenoxymethyl-fünfring-heteroaromaten
JPH02225485A (ja) 1989-02-27 1990-09-07 Taiho Yakuhin Kogyo Kk チエノピリミジン―３―酢酸誘導体
JP3121061B2 (ja) 1991-10-04 2000-12-25 塩野義製薬株式会社 アルコキシイミノアセトアミド類製造用中間体の製造法およびそれに用いる中間体
DE4137940A1 (de) 1991-11-18 1993-05-19 Basf Ag 3-isoxazolylphenylverbindungen, ihre herstellung und ihre verwendung
US5258551A (en) 1991-12-18 1993-11-02 Shionogi & Co., Ltd. Process for producing α-ketoamide derivative
WO1994017059A1 (en) 1993-01-29 1994-08-04 Nippon Soda Co., Ltd. Heterocyclic derivative
WO1994024095A1 (en) 1993-04-16 1994-10-27 Abbott Laboratories Immunosuppressive agents
TW276256B (pl) 1993-08-26 1996-05-21 Takeda Pharm Industry Co Ltd
JP3811196B2 (ja) 1993-08-26 2006-08-16 武田薬品工業株式会社 エンドセリン拮抗剤、チエノピリミジン誘導体およびその製造法
IL112721A0 (en) 1994-03-10 1995-05-26 Zeneca Ltd Azole derivatives
AU699272B2 (en) 1994-08-02 1998-11-26 Merck Sharp & Dohme Limited Azetidine, pyrrolidine and piperidine derivatives
GB9501865D0 (en) 1995-01-31 1995-03-22 Merck Sharp & Dohme Therapeutic agents
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
JPH09110873A (ja) 1995-08-17 1997-04-28 Takeda Chem Ind Ltd チエノピリミジン誘導体、その製造法および用途
EP0846119B1 (en) 1995-08-17 2002-11-13 Takeda Chemical Industries, Ltd. Thienopyrimidine derivatives, their production and use as endothelin antagonists
DE19536811A1 (de) 1995-10-02 1997-04-03 Basf Ag Zwischenprodukte und Verfahren zur Herstellung von substituierten Salicylsäurederivaten als Pflanzenschutzmittel
EP0880363B1 (en) 1996-02-13 2002-09-11 G.D. SEARLE & CO. Combinations, having immunosuppressive effects, containing a cyclooxygenase-2 inhibitor and a leukotriene a 4 hydrolase inhibitor
US6015789A (en) 1996-04-30 2000-01-18 Takeda Chemical Industries, Ltd. Combined use of GnRH agonist and antagonist
JP2007302703A (ja) 1996-04-30 2007-11-22 Takeda Chem Ind Ltd 医薬組成物
US6984644B2 (en) 1997-05-28 2006-01-10 Astrazeneca Ab Treatment of skin disorders using thieno[2,3-D]pyrimidinediones
SE9702001D0 (sv) 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
DE19754082A1 (de) 1997-12-05 1999-06-10 Knoll Ag Methode zur Bekämpfung der Fettleibigkeit
DE69940958D1 (de) 1998-12-23 2009-07-16 Glaxo Group Ltd Bestimmungsmethode fur liganden der nuklearen rezeptoren
ES2254163T3 (es) 1999-04-09 2006-06-16 Cell Therapeutics, Inc. Compuestos terapeuticos para inhibir la señalizacion de la interleucina-12 y metodos para el uso de la misma.
DE60016404T2 (de) 1999-06-11 2005-10-27 Allergan, Inc., Irvine Organosiliciumvebindungen mit der fähigkeit zur modulation von im zellkern lokalisierten hormonrezeptoren
EP1340749A4 (en) 2000-11-17 2007-09-05 Takeda Pharmaceutical ISOXAZOLE DERIVATIVES
JP2004518732A (ja) 2001-02-14 2004-06-24 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ阻害剤としてのチエノ’２，３−ｄピリミジンジオン誘導体
US20040131670A1 (en) 2001-04-17 2004-07-08 Ping Gao Pellicle-resistant gelatin capsule
US20040105884A1 (en) 2001-04-17 2004-06-03 Ping Gao Pharmaceutical dosage form comprising a sulfite compound
US20040105885A1 (en) 2001-04-17 2004-06-03 Ping Gao Gelatin capsule exhibiting reduced cross-linking
US20040105883A1 (en) 2001-04-17 2004-06-03 Ping Gao Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage
US7223791B2 (en) 2001-06-26 2007-05-29 Takeda Pharmaceutical Company Limited Function regulator for retinoid relative receptor
US7655658B2 (en) 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
EP1423113A4 (en) 2001-08-13 2007-04-18 Phenex Pharmaceuticals Ag NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS
WO2003016280A1 (en) 2001-08-13 2003-02-27 Lion Bioscience Ag Nr1h4 nuclear receptor binding compounds
EP1285914B1 (en) 2001-08-13 2007-12-19 PheneX Pharmaceuticals AG Nr1h4 nuclear receptor binding compounds
KR20040095239A (ko) 2002-02-27 2004-11-12 화이자 프로덕츠 인코포레이티드 Ａｃｃ 억제제
AU2003225903A1 (en) 2002-03-21 2003-10-08 Curagen Corporation Methods of using farnesoid x receptor (fxr) agonists
US7595311B2 (en) 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
NZ538339A (en) 2002-08-09 2007-01-26 Astrazeneca Ab Oxadiazoles as modulators of metabotropic glutamate receptor-5
EP1581525A2 (en) 2002-08-09 2005-10-05 AstraZeneca AB Compounds having an activity at metabotropic glutamate receptors
MXPA05001594A (es) 2002-08-09 2005-09-20 Astrazeneca Ab 1,2,4" oxadiazoles como moduladores de receptor-5 metabotropico de glutamato.
AU2003253165A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
EP1407774A1 (en) 2002-09-10 2004-04-14 LION Bioscience AG 2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds
AU2003290796A1 (en) 2002-11-14 2004-06-15 The Scripps Research Institute Non-steroidal fxr agonists
US20050143449A1 (en) 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
JP2006515838A (ja) 2002-11-22 2006-06-08 スミスクライン ビーチャム コーポレーション ファルネソイドｘ受容体アゴニスト
WO2004060058A2 (en) 2003-01-06 2004-07-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Herbicides inhibiting the action of plant acetyl-coa carboxylase for use as pesticides.
EP1591446B1 (en) 2003-01-29 2013-03-06 Takeda Pharmaceutical Company Limited Thienopyrimidine compounds and use thereof
WO2004087076A2 (en) 2003-03-31 2004-10-14 The Rockefeller University Methods for inhibiting adipogenesis and for treating type 2 diabetes
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005077345A1 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
BRPI0511099A (pt) 2004-05-14 2007-12-26 Irm Llc compostos e composições como moduladores de ppar
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
US7947691B2 (en) 2004-07-21 2011-05-24 Athersys, Inc. Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof
US20080269191A1 (en) 2004-10-13 2008-10-30 Ptc Therapeutics, Inc. Compounds for Nonsense Suppression, Use of These Compounds for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases
JP2008137894A (ja) 2005-03-22 2008-06-19 Nippon Kayaku Co Ltd 新規なアセチレン誘導体
TW200716576A (en) 2005-06-07 2007-05-01 Shionogi & Co Heterocyclic derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2007070796A1 (en) 2005-12-15 2007-06-21 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
WO2007076260A2 (en) 2005-12-19 2007-07-05 Smithkline Beecham Corporation Farnesoid x receptor agonists
US7560551B2 (en) 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
US7863302B2 (en) 2006-02-03 2011-01-04 Eli Lilly And Company Compounds and methods for modulating FX-receptors
CA2642220A1 (en) 2006-02-14 2007-08-23 Intercept Pharmaceuticals, Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions
CA2644996A1 (en) 2006-03-02 2007-09-13 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
JP2009531364A (ja) 2006-03-28 2009-09-03 ノバルティス アクチエンゲゼルシャフト アミド誘導体およびｇタンパク質関連疾患の処置のためのそれらの使用
EP2007759A4 (en) 2006-04-17 2010-12-22 Neuromed Pharmaceuticals Ltd ISOXAZOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
MX2008014854A (es) 2006-05-24 2008-12-05 Lilly Co Eli Antagonistas de fxr.
CL2007001451A1 (es) 2006-05-24 2008-01-11 Eli Lilly And Company Soc Organizada Bajo Las Leyes Del Estado De Indiana Compuestos derivados de [1,2,3]-tiazol-4-ilmetoxilo, agonista del receptor farnesoide x (fxr); composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar dislipidemia y enfermedades relacionadas.
EP2029600B1 (de) 2006-05-24 2012-03-14 Boehringer Ingelheim International GmbH Substituierte pteridine, die mit einem viergliedrigen heterocyclus substituiert sind
WO2007140200A2 (en) 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
EP2040713B1 (en) 2006-06-27 2014-06-18 Intercept Pharmaceuticals Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
EP2043651A2 (en) 2006-07-05 2009-04-08 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
EP2041114B1 (en) 2006-07-07 2016-03-02 NephroGenex, Inc. Inhibitors of advanced glycation end products
BRPI0712795A2 (pt) 2006-07-07 2012-09-04 Boehringer Ingelheim Int derivados de heteroarila substituìdos com fenila e uso dos mesmos como agentes antitumorais
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
US8193225B2 (en) 2006-10-13 2012-06-05 The Board Of Regents Of The University Of Texas System Isoxazole amides, derivatives and methods of chemical induction of neurogenesis
CL2007003035A1 (es) 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
US8501933B2 (en) 2006-11-09 2013-08-06 Roche Palo Alto Llc Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists
EP2121621B1 (en) 2006-12-08 2014-05-07 Exelixis Patent Company LLC Lxr and fxr modulators
GB0625842D0 (en) 2006-12-22 2007-02-07 Argenta Discovery Ltd Indolizine derivatives
US20090105251A1 (en) 2007-01-25 2009-04-23 Benjamin Jones Renin inhibitors
BRPI0721218A2 (pt) 2007-02-09 2013-01-01 Dow Agrosciences Llc processo para a oxidação de determinadas sulfiliminas substituìdas para sulfoximinas inseticidas
US7511149B2 (en) 2007-02-09 2009-03-31 Dow Agrosciences Llc Process for the oxidation of certain substituted sulfilimines to insecticidal sulfoximines
WO2008106006A1 (en) 2007-02-26 2008-09-04 Dow Agrosciences Llc Process for the preparation of certain substituted sulfilimines
EP2151440A4 (en) 2007-05-21 2010-10-20 Takeda Pharmaceutical Heterocyclic compound and use thereof
EA200901512A1 (ru) 2007-06-13 2010-06-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Агонисты фарнезоидных х-рецепторов
JP2008308448A (ja) 2007-06-15 2008-12-25 Sankyo Agro Kk （３−硫黄原子置換フェニル）へテロアリール誘導体
WO2008155054A1 (en) 2007-06-20 2008-12-24 F. Hoffmann-La Roche Ag Farnesoid-x-receptor mutants, and crystallisation thereof
CA2690406A1 (en) 2007-07-02 2009-01-08 Glaxosmithkline Llc Farnesoid x receptor agonists
JP2010531850A (ja) 2007-07-02 2010-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物
EP2178877A1 (en) 2007-07-13 2010-04-28 GlaxoSmithKline LLC Anti-viral compounds, compositions, and methods of use
US20090197880A1 (en) 2007-07-13 2009-08-06 Genelabs Technologies, Inc. Anti-viral compounds, compositions, and methods of use
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
CN101790374A (zh) 2007-08-01 2010-07-28 H.隆德贝克有限公司 Kcnq钾通道开放剂用于减轻多巴胺能系统受到干扰的障碍或病症的症状或治疗这种障碍或病症的用途
US8188080B2 (en) 2007-10-17 2012-05-29 Sanford-Burnham Medical Research Institute VHR protein tyrosine phosphatase inhibitors, compositions and methods of use
US20090143451A1 (en) 2007-11-14 2009-06-04 Andrews William H Compounds that increase telomerase reverse transcriptase (tert) expression and methods for using the same
EA017144B1 (ru) 2007-12-21 2012-10-30 Астразенека Аб N-содержащие бициклические производные для применения при лечении состояний, связанных с андрогенным рецептором
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
US20120015988A1 (en) 2008-05-13 2012-01-19 Boehringer Ingelheim International Gmbh Sulfone Compounds Which Modulate The CB2 Receptor
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
EP2291372A4 (en) 2008-05-19 2012-04-25 Burnham Inst Medical Research MODULATORS OF ALKALINE PHOSPHATASE FROM DARM AND APPLICATIONS THEREOF
EP2128158A1 (en) 2008-05-26 2009-12-02 Phenex Pharmaceuticals AG Heterocyclic cyclopropyl-substituted FXR binding compounds
WO2009152083A1 (en) 2008-06-10 2009-12-17 Plexxikon, Inc. 5h-pyrr0l0 [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
AU2009259839A1 (en) 2008-06-20 2009-12-23 Kinemed, Inc. Compositions for the treatment of fibrotic diseases or conditions
US8252939B2 (en) 2008-06-23 2012-08-28 Basf Se Sulfoximinamide compounds for combating animal pests
WO2010006096A1 (en) 2008-07-11 2010-01-14 Smithkline Beecham Corporation Processes for the preparation of anti-viral compounds and compositions containing them
WO2010025035A1 (en) 2008-08-25 2010-03-04 Dow Global Technologies Inc. Process for preparing isoxazole compounds
WO2010033906A2 (en) 2008-09-19 2010-03-25 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
ES2446593T3 (es) 2008-09-25 2014-03-10 F. Hoffmann-La Roche Ag Indazol 2,3-sustituido o 4,5,6,7-tetrahidro-indazoles como moduladores de FXR contra la diislipidemia y las enfermedades asociadas
MX2011002793A (es) 2008-09-25 2011-04-05 Hoffmann La Roche Derivados de 3-amino-indazol o de 3-amino-4,5,6,7-tetrahidro-indaz ol.
CA2736880A1 (en) 2008-09-26 2010-04-01 Wyeth Llc 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors
US20100216827A1 (en) 2008-10-21 2010-08-26 Metabolex, Inc. Aryl gpr120 receptor agonists and uses thereof
EP2351743A4 (en) 2008-10-27 2012-05-09 Takeda Pharmaceutical BICYCLIC COMPOUND
US20100113473A1 (en) 2008-10-30 2010-05-06 Player Mark R Aryl amide compound as an acetyl coenzyme a carboxylase inhibitor
FR2937972B1 (fr) 2008-11-04 2013-03-29 Galderma Res & Dev Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
CA2744946A1 (en) 2009-02-04 2010-08-12 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
WO2010093191A2 (en) 2009-02-13 2010-08-19 Lg Life Sciences Ltd. Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
FR2943059A1 (fr) 2009-03-16 2010-09-17 Sanofi Aventis Derives de n-°6-aza-bicyclo°3.2.1!oct-5-yl)-aryl-methyl!- heterobenzamide,leur preparation et leur application en therapeutique
JP2012532175A (ja) 2009-07-06 2012-12-13 ビーエーエスエフ ソシエタス・ヨーロピア 無脊椎動物系害虫防除用ピリダジン化合物
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
EP2456308A2 (en) 2009-07-24 2012-05-30 Basf Se Pyridine derivatives for controlling invertrebate pests
US9212177B2 (en) 2009-08-05 2015-12-15 Versitech Limited Antiviral compounds and methods of making and using thereof
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
AU2010291834A1 (en) 2009-09-04 2012-03-15 Zalicus Pharmaceuticals Ltd. Substituted heterocyclic derivatives for the treatment of pain and epilepsy
WO2011047129A1 (en) 2009-10-15 2011-04-21 Southern Research Institute Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such
CA2784553C (en) 2009-12-29 2014-08-19 Poxel Thieno [2,3-b] pyridinedione activators of ampk and therapeutic uses thereof
WO2011109059A1 (en) 2010-03-01 2011-09-09 Gtx, Inc. Compounds for treatment of cancer
WO2011156640A2 (en) 2010-06-09 2011-12-15 Afraxis, Inc. 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS
WO2012058531A2 (en) 2010-10-29 2012-05-03 North Carolina State University Modulation of response regulators by imidazole derivatives
TWI408128B (zh) 2010-12-03 2013-09-11 Nat Univ Tsing Hua 間-三聯苯衍生物及其在有機發光二極體之應用
EP2649061B1 (en) 2010-12-10 2015-05-13 Rottapharm Biotech S.r.l. Pyridine amide derivatives as ep4 receptor antagonists
WO2012087520A1 (en) 2010-12-20 2012-06-28 Irm Llc Compositions and methods for modulating farnesoid x receptors
CN103391937A (zh) 2010-12-20 2013-11-13 Irm责任有限公司 用于调控法尼醇x受体的组合物和方法
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
WO2012090219A2 (en) 2010-12-31 2012-07-05 Jubilant Biosys Ltd. Thiazole compounds useful as acetyl-coa carboxylase (acc) inhibitors
FR2981933B1 (fr) 2011-11-02 2013-11-15 Galderma Res & Dev Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
KR102033806B1 (ko) 2011-11-11 2019-10-17 길리어드 아폴로, 엘엘씨 Ａｃｃ 억제제 및 이의 용도
KR20190121871A (ko) 2012-06-19 2019-10-28 인터셉트 파마슈티컬즈, 인크. 오베티콜산의 제조법, 용도 및 고체 형태
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
MA38385A1 (fr) 2013-04-22 2017-09-29 Cadila Healthcare Ltd Nouvelle composition pour la stéatose hépatique non alcoolique (nafld)
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
AU2014262546B2 (en) 2013-05-10 2018-11-08 Gilead Apollo, Llc ACC inhibitors and uses thereof
EP2994138A4 (en) 2013-05-10 2016-12-28 Nimbus Apollo Inc ACC-HEMMER AND USES THEREOF
PT2997035T (pt) 2013-05-14 2018-07-18 Intercept Pharmaceuticals Inc Derivados de 11-hidroxilo substituídos em 6 de ácidos biliares e seus conjugados de aminoácido como moduladores do recetor farnesoide x
TWI696462B (zh) 2013-07-10 2020-06-21 日商興和股份有限公司 非酒精性脂肪性肝疾病治療劑
WO2015007451A1 (en) 2013-07-15 2015-01-22 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
BR112016002268B1 (pt) 2013-08-01 2022-11-01 The Penn State Research Foundation Uso de inibidores do receptor x farnesoide
MY186752A (en) 2013-09-11 2021-08-18 Inst Nat Sante Rech Med Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection
US20150082981A1 (en) 2013-09-20 2015-03-26 E I Du Pont De Nemours And Company Capture of trifluoromethane using ionic liquids
CN104513213A (zh) 2013-09-28 2015-04-15 山东亨利医药科技有限责任公司 Fxr激动剂
US20150119345A1 (en) 2013-10-29 2015-04-30 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of gastrointestinal infections
TWI662027B (zh) 2013-11-05 2019-06-11 諾華公司 用於調節泫尼酯（ｆａｒｎｅｓｏｉｄ）ｘ受體之組合物及方法
WO2015116856A2 (en) 2014-01-29 2015-08-06 City Of Hope Farnesoid x receptor antagonists
US10077268B2 (en) 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
WO2015138986A1 (en) 2014-03-13 2015-09-17 Salk Institute For Biological Studies Fxr agonists and methods for making and using
JP2017511304A (ja) 2014-03-13 2017-04-20 ソーク インスティチュート フォー バイオロジカル スタディーズ フェキサラミン類似体ならびに作製方法および使用方法
CA2945535A1 (en) 2014-04-14 2015-10-22 Grunenthal Gmbh Heteroaryl substituted heterocyclyl sulfones
WO2015162538A1 (en) 2014-04-21 2015-10-29 Lupin Limited Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
WO2015162244A1 (en) 2014-04-25 2015-10-29 Basf Se N-acylamidine compounds
WO2015165960A1 (en) 2014-04-30 2015-11-05 Basf Se N-acylamidine compounds
SMT202000070T1 (it) 2014-05-29 2020-03-13 Bar Pharmaceuticals S R L Derivati del colano per l'uso del trattamento e/o la prevenzione di malattie mediate da fxr e tgr5/gpbar1
CN104045635A (zh) 2014-06-23 2014-09-17 华东理工大学 3,4,5-三取代异恶唑类化合物及其用途
WO2016046311A1 (en) 2014-09-25 2016-03-31 Astrazeneca Ab Combination of an omega-3 fatty acid and an sglt-2 inhibitor for treating diseases of the liver
WO2016054560A1 (en) 2014-10-02 2016-04-07 Flatley Discovery Lab Isoxazole compounds and methods for the treatment of cystic fibrosis
EP3006939A1 (en) 2014-10-06 2016-04-13 Gilead Sciences, Inc. Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation
CN106716665B9 (zh) 2014-10-27 2018-12-07 株式会社Lg化学 有机电致发光器件
KR20170094184A (ko) 2014-11-06 2017-08-17 이난타 파마슈티칼스, 인코포레이티드 Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
MX370480B (es) 2014-11-21 2019-12-16 Akarna Therapeutics Ltd Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
WO2016086134A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
WO2016086115A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
AU2015353473A1 (en) 2014-11-26 2017-06-08 Enanta Pharmaceuticals, Inc. Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
EP3034501A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
AU2015365481B2 (en) 2014-12-18 2018-08-09 Novartis Ag Azabicyclooctane derivatives as FXR agonists for use in the treatment of liver and gastrointestinal diseases
EA201892625A1 (ru) * 2015-01-09 2019-07-31 Джилид Аполло, Ллс КОМБИНИРОВАННАЯ ТЕРАПИЯ С ПРИМЕНЕНИЕМ ИНГИБИТОРА АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ
ES2907461T3 (es) 2015-01-20 2022-04-25 Boehringer Ingelheim Animal Health Usa Inc Compuestos antihelmínticos, composiciones y procedimientos de uso de los mismos
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
US10100285B2 (en) 2015-04-03 2018-10-16 Propagenix Inc. Ex vivo proliferation of epithelial cells
CN106146483A (zh) 2015-04-23 2016-11-23 上海迪诺医药科技有限公司 杂环类法尼酯衍生物x受体调节剂
GB201507340D0 (en) 2015-04-29 2015-06-10 Univ St Andrews Light emitting devices and compounds
WO2017011466A1 (en) 2015-07-13 2017-01-19 Zwiebel Laurence J Thermal volatilization of orco agonists
EP3892717A1 (en) 2015-09-11 2021-10-13 Propagenix Inc. Ex vivo proliferation of epithelial cells
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
SI3380480T1 (sl) 2015-11-25 2023-04-28 Gilead Apollo, Llc Pirazolni inhibitorji ACC in uporabe le-teh
CN108290902B (zh) 2015-11-25 2021-08-31 吉利德阿波罗公司 酯类acc抑制剂及其用途
MX2018006285A (es) 2015-11-25 2018-09-07 Gilead Apollo Llc Composiciones fungicidas que contienen derivados de 2,4-dioxido-1,4-dihidrotieno[2,3-d] pirimidina.
EA201890926A1 (ru) 2015-11-25 2018-12-28 Джилид Аполло, Ллс ТРИАЗОЛОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ
UY37005A (es) 2015-12-04 2017-06-30 Bristol-Myers Squibb Company Una Corporacion Del Estado De Delaware Hidroxipirimidinonas sustituidas como agonistas del receptor de apelina y sus usos
TW201734002A (zh) 2015-12-11 2017-10-01 拜耳作物科學股份有限公司 作為殺蟲劑之經取代的丙二醯胺類
CN106946867B (zh) 2016-01-06 2019-11-12 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和用途
EP3190103A1 (en) 2016-01-08 2017-07-12 Rijksuniversiteit Groningen Inhibitors of the pd-1/pd-l1 protein/protein interaction
AU2017204979B2 (en) 2016-01-10 2020-11-19 Provincial Health Services Authority 18/19F-labelled compounds which target the prostate specific membrane antigen
WO2017122209A2 (en) 2016-01-12 2017-07-20 Yeda Research And Development Co. Ltd. NF-kappaB INHIBITORS
WO2017128896A1 (zh) 2016-01-26 2017-08-03 江苏豪森药业集团有限公司 Fxr激动剂及其制备方法和应用
CN107021957A (zh) 2016-02-01 2017-08-08 山东轩竹医药科技有限公司 Fxr受体激动剂
WO2017133521A1 (zh) 2016-02-01 2017-08-10 山东轩竹医药科技有限公司 Fxr受体激动剂
CN107021958A (zh) 2016-02-01 2017-08-08 山东轩竹医药科技有限公司 Fxr受体激动剂
TW201741307A (zh) 2016-02-22 2017-12-01 艾洛斯生物製藥公司 Ｆｘｒ調節劑及其使用方法
CA3172549A1 (en) 2016-03-02 2017-09-08 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
CN107224583A (zh) 2016-03-24 2017-10-03 中美华世通生物医药科技（武汉）有限公司 药物组合物及其用途
FR3050112B1 (fr) 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
WO2017189652A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017189663A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017189651A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017201155A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
WO2017201152A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10144729B2 (en) 2016-05-18 2018-12-04 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
US10682344B2 (en) 2016-06-03 2020-06-16 Chemocentryx, Inc. Method of treating liver fibrosis
KR102269305B1 (ko) 2016-06-13 2021-06-25 길리애드 사이언시즈, 인코포레이티드 Fxr (nr1h4) 조정 화합물
AR108711A1 (es) 2016-06-13 2018-09-19 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
PH12018502633B1 (en) 2016-06-13 2023-02-01 Cancer Research Tech Ltd Substituted pyridines as inhibitors of dnmt1
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
US11091482B2 (en) 2016-08-23 2021-08-17 Ardelyx, Inc. Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators
MA55632A (fr) 2016-08-23 2022-02-16 Ardelyx Inc Procédé de preparation de modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques
WO2018059314A1 (zh) 2016-09-28 2018-04-05 四川科伦博泰生物医药股份有限公司 氮杂双环衍生物及其制备方法和用途
CN109983010A (zh) 2016-09-29 2019-07-05 拜耳作物科学股份公司 作为用于作物保护的杀真菌剂的1-[2-(1-氯环丙基)-2-羟基-3-(3-苯基-1,2-噁唑-5-基)丙基]-1h-咪唑-5-甲腈衍生物及相关化合物
MX2019003790A (es) 2016-10-04 2019-09-26 Enanta Pharm Inc Analogos de isoxazol como agonistas de fxr y metodos de uso de los mismos.
DK3528817T3 (da) 2016-10-18 2022-08-08 Madrigal Pharmaceuticals Inc Fremgangsmåder til behandling af leverforstyrrelser eller lipidforstyrrelser med en thr-beta-agonist
CN107973790A (zh) 2016-10-22 2018-05-01 合帕吉恩治疗公司 杂环fxr调节剂
CA3043284C (en) 2016-11-10 2022-06-28 Galmed Research And Development Ltd. Treatment for fibrosis
CN109937040A (zh) 2016-11-11 2019-06-25 吉利德科学公司 治疗肝病的方法
CN106588804B (zh) 2016-12-09 2018-11-09 都创(上海)医药科技有限公司 一种作为类法尼醇x受体(fxr)的化合物的制备方法
CN106632294A (zh) 2016-12-15 2017-05-10 宁波百纳西药业有限公司 一种螺环化合物及其药物用途
CN106748922B (zh) 2017-01-12 2019-02-01 中国药科大学 一类新型砜酸衍生物、其制备方法及其作为药物的用途
CN108341830B (zh) 2017-01-22 2021-03-02 广东东阳光药业有限公司 噻吩并嘧啶衍生物及其在药物中的应用
ES2963841T3 (es) 2017-03-03 2024-04-02 Gilead Sciences Inc Procesos para preparar inhibidores de ACC y formas sólidas del mismo
PL3600309T3 (pl) 2017-03-28 2022-11-07 Gilead Sciences, Inc. Skojarzenia terapeutyczne do leczenia chorób wątroby
CN106955288B (zh) 2017-03-30 2020-01-10 复旦大学附属中山医院 Fxr激动剂在制备治疗脂肪肉瘤相关疾病药物中的用途
AU2018250614A1 (en) 2017-04-12 2019-10-17 Gilead Sciences, Inc. Methods of treating liver disease
WO2018190643A1 (en) 2017-04-12 2018-10-18 Il Dong Pharmaceutical Co., Ltd. An isoxazole derivatives as nuclear receptor agonists and used thereof
US20210121493A1 (en) 2017-07-25 2021-04-29 Cedars-Sinai Medical Center Methods for treating liver diseases
KR20190036705A (ko) 2017-09-28 2019-04-05 한미약품 주식회사 (2r)-2-(2-메톡시페닐)-2-(옥산-4-일옥시)에탄-1-올 화합물의 신규 제조방법 및 이에 사용되는 중간체
KR20220103807A (ko) 2017-10-06 2022-07-22 길리애드 사이언시즈, 인코포레이티드 Acc 억제제를 포함하는 조합 요법
AU2019373244B2 (en) 2018-10-30 2022-05-26 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
CN113302190B (zh) 2019-01-15 2024-10-18 吉利德科学公司 Fxr(nr1h4)调节化合物
CA3129949C (en) 2019-02-19 2024-04-30 Gilead Sciences, Inc. Solid forms of fxr agonists
US20200315972A1 (en) 2019-03-11 2020-10-08 Gilead Sciences, Inc. Formulations of a compound and uses thereof

Also Published As

Publication number Publication date
ES2927019T3 (es) 2022-11-02
EP3600309A1 (en) 2020-02-05
SI4122464T1 (sl) 2024-07-31
US20210015818A1 (en) 2021-01-21
CA3055581A1 (en) 2018-10-04
KR20190126920A (ko) 2019-11-12
JP6906626B2 (ja) 2021-07-21
SI3600309T1 (sl) 2022-10-28
US20240165119A1 (en) 2024-05-23
EP3600309B1 (en) 2022-06-22
TWI663975B (zh) 2019-07-01
JP2021038259A (ja) 2021-03-11
JP2020512349A (ja) 2020-04-23
AU2021202387A1 (en) 2021-05-20
ES2982801T3 (es) 2024-10-17
TW201902482A (zh) 2019-01-16
KR20220119520A (ko) 2022-08-29
PL4122464T3 (pl) 2024-09-16
PT3600309T (pt) 2022-10-03
KR102743630B1 (ko) 2024-12-18
AU2018243719B2 (en) 2021-01-21
EP4424364A3 (en) 2024-11-27
CN110461328A (zh) 2019-11-15
EP4122464B1 (en) 2024-05-15
CA3055581C (en) 2023-03-14
EP4122464A1 (en) 2023-01-25
US11833150B2 (en) 2023-12-05
US20180280394A1 (en) 2018-10-04
AU2018243719A1 (en) 2019-09-19
EP4424364A2 (en) 2024-09-04
PT4122464T (pt) 2024-06-27
KR20240091322A (ko) 2024-06-21
WO2018183193A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
PL4122464T3 (pl) Kombinacje terapeutyczne do leczenia chorób wątroby
IL290149A (en) Combined treatment for cancer
HK1258588A1 (zh) 用於治療眼科疾病的化合物和製劑
SG11202104461XA (en) Therapeutic methods
HK1247129A1 (zh) 治療癌症的聯合療法
SG11201705093UA (en) Composition for treating il-6-related diseases
SG10201913409VA (en) Methods for solid tumor treatment
HK1251475A1 (zh) 用於癌症治療的聯合療法
RS59048B1 (sr) Terapeutski agensi za neurodegenerativne bolesti
HK1258727A1 (zh) 治療性化合物
GB201603104D0 (en) Therapeutic agents
GB201716942D0 (en) Therapeutic compounds
ZA201904736B (en) Targeted doxorubicin-gold nanoconjugates for tumor therapy
IL273929A (en) Therapeutic agents for neurodegenerative diseases
GB201622116D0 (en) Treatment of liver disease
GB201819936D0 (en) Therapeutic methods
GB201712394D0 (en) Therapeutic compounds
GB201712388D0 (en) Therapeutic compounds
GB201712392D0 (en) Therapeutic compounds
GB201712390D0 (en) Therapeutic compounds
GB201712393D0 (en) Therapeutic compounds
GB201712395D0 (en) Therapeutic compounds
GB201620948D0 (en) Therapeutic agents
SG11201801083UA (en) Tumor therapeutic agent
GB201616563D0 (en) Therapeutic agents